The Fc protein and glyco-engineered antibodies market
The Fc protein and glyco-engineered antibodies market is projected to grow at a CAGR of over 30% during 2021-2030, claims Roots Analysis
With the emergence of blockbuster drugs, such as Gazyva®
(for Chronic Lymphocytic Leukemia) and POTELEGIO® (for Sézary syndrome), Fc
engineered antibodies have garnered significant interest in the medical
community, for various clinical conditions
London
Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings.
Over time, a substantial body of evidence has validated the
therapeutic applications of Fc engineering platforms; Fc modified antibodies have shown to augment
the various immune effector functions, such as antibody-dependent cellular
cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC),
antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life
of the molecule
To order this 250+ page report,
which features 100+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Key Market Insights
The Fc engineered antibodies pipeline features more than 125 marketed
drugs / drug development programs
Around 15% Fc protein and glyco-engineered antibodies are
marketed, while close to 75% are being evaluated in different phases of
clinical trials and 10% in preclinical studies. Examples of marketed Fc
engineered antibodies include Gazvya®, Imfinzi®, MONJUVI® and Skyrizi®.
Around 30 companies claim to be engaged in the
development of Fc protein and glyco-engineered antibodies
Around 55% of the aforementioned players are large
companies (with more than 5000 employees). It is worth highlighting that,
majority of the developers engaged in this domain (54%) are based in North
America, followed by Europe (26%) and Asia-Pacific (20%).
Over 1,800 clinical trials are currently evaluating the
therapeutic effects of Fc protein and glyco-engineered antibodies, worldwide
It is worth mentioning that
most of the trials were / are being conducted in North America (35%) region;
however, more than 91% of
the patients enrolled in trials conducted in North America were enrolled in
different sites in the United States. Further, 43% of the trials are being
sponsored by non-industry players.
To request a sample
copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market/request-sample.html
Key Questions
Answered
§ Who are the leading industry and non-industry
players engaged in the development of Fc protein and glyco-engineered
antibodies?
§ Which are the key disease indications being
targeted by Fc engineered antibodies?
§ Which partnership models are commonly adopted by
stakeholders engaged in this domain?
§ Which geographies are the most active in conducting
clinical trials on Fc protein and glyco-engineered antibodies?
§ Which are the leading administering institutes
supporting the research related to Fc protein and glyco-engineered
antibodies?
§ How has the intellectual property landscape in this
market evolved over the years?
§ Which key factors are likely to influence the
evolution of this market?
§ How is the current and future market opportunity
likely to be distributed across key market segments?
For additional details, please visit
or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. TIL-based Therapies Market,
2021-2030
2. TCR-based Therapies Market,
2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415
Comments
Post a Comment